Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06737380 · ClinicalTrials.gov registry record · Phase 1

UC-MSC Cell Therapy Study for Systemic Lupus Erythematosus (SLE) Patients

A Phase 1 study of Systemic Lupus Erythematosus and Systemic Lupus Erythematosus (SLE), sponsored by LiveKidney.Bio.

Recruiting
Registry status
Phase 1
Development phase
10
Enrollment target
1
Study location

NCT06737380 is a Phase 1 study of Systemic Lupus Erythematosus and Systemic Lupus Erythematosus (SLE) that is actively recruiting participants, run by LiveKidney.Bio. The registered enrollment target is 10 participants, below the 380-participant average among 99 other Systemic Lupus Erythematosus trials with a reported enrollment target (97% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06737380, a Phase 1 study of Systemic Lupus Erythematosus and Systemic Lupus Erythematosus (SLE), is actively recruiting participants, sponsored by LiveKidney.Bio.

RECRUITING
Registry status
Phase 1
Development phase
10 participants
Enrollment target
1
Study location

Study Summary

The goal of this clinical trial is to evaluate the safety and effectiveness of UC-MSCs in adults with systemic lupus erythematosus (SLE). The main questions this study aims to answer are: 1. Can UC-MSCs improve kidney function and reduce SLE disease activity? 2. Are UC-MSCs safe and well-tolerated in this patient population? Participants in this study will: * Receive UC-MSCs in a single dose in addition to standard of care treatment. * Provide blood and urine samples for laboratory assessments, including biomarkers and immune profiling (e.g., cytokines, complement proteins, and autoantibodies). * Attend regular clinic visits for physical exams, disease activity scoring, and imaging tests to monitor kidney health. * Complete assessments for safety, such as monitoring for adverse events and changes in laboratory values. This study aims to provide new insights into treatment options for SLE and lupus nephritis, addressing an unmet medical need in this population.

Conditions Studied

Systemic Lupus Erythematosus Systemic Lupus Erythematosus (SLE) Lupus SLE Systemic Lupus Erthematosus

Interventions

  • DIAGNOSTIC_TEST Physical examination
  • DIAGNOSTIC_TEST Electrocardiogram
  • OTHER SF-36 questionnaire
  • DIAGNOSTIC_TEST Clinical laboratory evaluations - Serology
  • DIAGNOSTIC_TEST Clinical laboratory evaluations - Biochemistry

Study Locations (1)

South Carolina

  • Medical University of South Carolina - Charleston

Trial Details

FieldValue
Enrollment Target 10 participants
Start Date 2025-01-07
Est. Completion 2026-07
Phase Phase 1

Sponsor

LiveKidney.Bio

1 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT06737380

The ClinicalTrials.gov registry entry for NCT06737380 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 10 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 380-participant average among 99 other Systemic Lupus Erythematosus trials with a reported enrollment target (97% lower). The listed sponsor is LiveKidney.Bio, which has 1 total studies on file at ClinicalTrials.gov.

The record links to 5 conditions, with Systemic Lupus Erythematosus appearing as the primary indexed condition, and to 5 interventions - of which Physical examination is the first listed.

NCT06737380 reports 1 study location spanning 1 distinct geographic area - top geographies include South Carolina.

Frequently Asked Questions

What is clinical trial NCT06737380 about?

NCT06737380 is a clinical study titled "UC-MSC Cell Therapy Study for Systemic Lupus Erythematosus (SLE) Patients". The goal of this clinical trial is to evaluate the safety and effectiveness of UC-MSCs in adults with systemic lupus erythematosus (SLE). The main questions this study aims to answer are: 1. Can UC-MSCs improve kidney function and reduce SLE disease activity? 2. Are UC-MSCs safe and well-tolerated...

What is the current status of trial NCT06737380?

This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 10 participants. The study started on 2025-01-07. Estimated completion is 2026-07.

What conditions does trial NCT06737380 study?

This clinical trial studies the following conditions: Systemic Lupus Erythematosus, Systemic Lupus Erythematosus (SLE), Lupus, SLE, Systemic Lupus Erthematosus.

What interventions are being tested in trial NCT06737380?

The interventions under investigation include: Physical examination (DIAGNOSTIC_TEST), Electrocardiogram (DIAGNOSTIC_TEST), SF-36 questionnaire (OTHER), Clinical laboratory evaluations - Serology (DIAGNOSTIC_TEST), Clinical laboratory evaluations - Biochemistry (DIAGNOSTIC_TEST).

Who is sponsoring clinical trial NCT06737380?

This trial is sponsored by LiveKidney.Bio, which has 1 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06737380 being conducted?

This trial has 1 study location across South Carolina. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Systemic Lupus Erythematosus

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Systemic Lupus Erythematosus

All registered trials for this condition

Systemic Lupus Erythematosus (SLE)

All registered trials for this condition

South Carolina

All trials with a study site in South Carolina

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.